Active Peptic Ulcer Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Active Peptic Ulcer Disease

MalaCards integrated aliases for Active Peptic Ulcer Disease:

Name: Active Peptic Ulcer Disease 12 15
Gi Bleeding 12 15
Gastrointestinal Hemorrhage 71
Active Peptic Ulcer 71


External Ids:

Disease Ontology 12 DOID:749
UMLS 71 C0017181 C1706705

Summaries for Active Peptic Ulcer Disease

MalaCards based summary : Active Peptic Ulcer Disease, also known as gi bleeding, is related to dieulafoy lesion and gastric antral vascular ectasia, and has symptoms including vomiting, fatigue and fever. An important gene associated with Active Peptic Ulcer Disease is ATP12A (ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Complement and coagulation cascades. The drugs Tranexamic Acid and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and testes, and related phenotypes are cardiovascular system and digestive/alimentary

Related Diseases for Active Peptic Ulcer Disease

Diseases related to Active Peptic Ulcer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 458)
# Related Disease Score Top Affiliating Genes
1 dieulafoy lesion 31.0 ATP4A ATP12A
2 gastric antral vascular ectasia 30.6 SST ATP4A ATP12A
3 chronic intestinal vascular insufficiency 30.5 ATP4A ATP12A
4 esophagitis 30.4 PTGS2 HRH2 CYP2C19
5 eosinophilic gastritis 30.2 ATP4A ATP12A
6 angiodysplasia 30.1 VWF SST F3 ATP4A ATP12A ACVRL1
7 duodenal ulcer 30.1 SST HRH2 CYP2C19
8 acquired von willebrand syndrome 30.0 VWF F7 F3
9 gastrointestinal ulceration, recurrent, with dysfunctional platelets 30.0 PTGS2 PTGS1 HRH2
10 gastrointestinal stromal tumor 30.0 SST PTGS2 KIT ANO1
11 endocarditis 29.9 F2 CRP ALB
12 zollinger-ellison syndrome 29.9 SST HRH2 ATP4A ATP12A
13 esophageal varix 29.9 SST F3 F2 ATP4A ATP12A ALB
14 liver cirrhosis 29.8 SST F3 F2 CYP3A4 ALB
15 factor x deficiency 29.8 F7 F3 F2
16 portal hypertension 29.8 VWF SST F3 F2 ALB
17 obstructive jaundice 29.6 KIT F2 CRP ALB
18 ileus 29.6 SST F2 CRP
19 inflammatory myofibroblastic tumor 29.5 KIT FLG2 ANO1 ACVRL1
20 deficiency anemia 29.5 KIT CRP ATP4A ATP12A ALB
21 hemorrhoid 29.5 F2 CRP ATP4A ATP12A ALB
22 duodenitis 29.5 CRP ATP4A ATP12A ALB
23 gastric ulcer 29.4 SST PTGS2 PTGS1 HRH2 CYP2C19
24 uremia 29.4 VWF CRP ALB
25 purpura 29.3 VWF F3 F2 CRP
26 celiac disease 1 29.3 CRP ATP4A ATP12A ALB
27 thrombocytopenia 29.3 VWF F3 F2 CRP ALB
28 meckel diverticulum 29.2 SST KIT HRH2 FLG2 CRP
29 peptic ulcer disease 29.2 SST PTGS2 PTGS1 HRH2 CYP2C19 ATP4A
30 gastroesophageal reflux 29.2 PTGS2 PTGS1 HRH2 CYP2C19 ATP4A ATP12A
31 gastritis 29.1 SST PTGS2 PTGS1 HRH2 CYP2C19 ATP4A
32 pneumonia 29.0 HRH2 F3 F2 CRP ALB
33 aspiration pneumonia 28.9 F3 F2 CRP ATP4A ATP12A ALB
34 acute myocardial infarction 28.8 VWF F7 F3 CRP
35 atrial fibrillation 28.7 VWF P2RY12 F3 F2 CRP ALB
36 intussusception 28.6 KIT FLG2 CRP ANO1 ALB
37 thrombosis 28.6 VWF PTGS1 P2RY12 F7 F3 F2
38 intestinal obstruction 28.0 SST KIT FLG2 CRP ATP4A ATP12A
39 vascular disease 27.9 VWF PTGS2 PTGS1 F3 F2 CYP2C19
40 heart disease 27.7 VWF PTGS1 F7 F3 F2 CRP
41 vagus nerve disease 10.6 ATP4A ATP12A
42 hemangioma of intra-abdominal structure 10.6 ATP4A ATP12A
43 acquired gastric outlet stenosis 10.6 ATP4A ATP12A
44 displacement of cardia through esophageal hiatus 10.6 ATP4A ATP12A
45 benzylpenicillin allergy 10.6 ATP4A ATP12A
46 granulomatous gastritis 10.6 ATP4A ATP12A
47 bacterial esophagitis 10.6 ATP4A ATP12A
48 lingual goiter 10.6 ATP4A ATP12A
49 gastrojejunal ulcer 10.6 ATP4A ATP12A
50 laryngeal tuberculosis 10.6 ATP4A ATP12A

Comorbidity relations with Active Peptic Ulcer Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 141)

Acquired Thrombocytopenia Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Acute Pancreatitis Acute Vascular Insufficiency of Intestine
Alcoholic Gastritis Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Alzheimer Disease
Anus Disease Aortic Valve Disease 1
Ascending Colon Cancer Atrophic Gastritis
Bacteremia 2 Benign Essential Hypertension
Bleeding Disorder, Platelet-Type, 11 Bronchitis
Bronchopneumonia Candidiasis
Cardiac Arrest Cardiogenic Shock
Cecal Benign Neoplasm Cerebral Atherosclerosis
Cerebrovascular Disease Cholestasis
Chronic Intestinal Vascular Insufficiency Chronic Pulmonary Heart Disease
Chronic Ulcer of Skin Chylomicron Retention Disease
Colon Carcinoma in Situ Colorectal Cancer
Conjunctivitis Crohn's Disease
Cystitis Decubitus Ulcer
Deficiency Anemia Dermatomycosis
Descending Colon Cancer Disseminated Intravascular Coagulation
Duodenitis Duodenum Cancer
Dysthymic Disorder Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Esophageal Cancer
Esophageal Candidiasis Esophageal Disease
Esophageal Varix Esophagitis

Graphical network of the top 20 diseases related to Active Peptic Ulcer Disease:

Diseases related to Active Peptic Ulcer Disease

Symptoms & Phenotypes for Active Peptic Ulcer Disease

UMLS symptoms related to Active Peptic Ulcer Disease:

vomiting, fatigue, fever, edema, pruritus, nausea and vomiting, abdominal pain, chest pain, hemoptysis, constipation, headache, syncope, diarrhea, pain, nausea, chronic pain, sciatica, halitosis, icterus, coughing, vertigo/dizziness, symptoms, dyspepsia, heartburn, gastrointestinal gas, digestive system symptom, pelvic pain, blood in stool

MGI Mouse Phenotypes related to Active Peptic Ulcer Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10 ACVRL1 ALB ANO1 CRP F2 F3
2 digestive/alimentary MP:0005381 9.93 ACVRL1 ALB ANO1 ATP12A ATP4A F2
3 homeostasis/metabolism MP:0005376 9.86 ACVRL1 ALB ANO1 ATP12A ATP4A CRP
4 normal MP:0002873 9.28 ACVRL1 ALB F2 F3 F7 KIT

Drugs & Therapeutics for Active Peptic Ulcer Disease

Drugs for Active Peptic Ulcer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 226)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Tranexamic Acid Approved Phase 4 1197-18-8 5526
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Prucalopride Approved Phase 4 179474-81-8
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
Thrombin Approved, Investigational Phase 4
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
Dalteparin Approved Phase 4 9005-49-6
13 Bemiparin Approved, Investigational Phase 4 91449-79-5
Sucralfate Approved Phase 4 54182-58-0
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
AT-101 Approved, Investigational Phase 4 652-67-5, 90141-22-3 12597
Prazosin Approved Phase 4 19216-56-9 4893
Acetaminophen Approved Phase 4 103-90-2 1983
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
Dobutamine Approved Phase 4 34368-04-2 36811
Clarithromycin Approved Phase 4 81103-11-9 84029
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
Linaclotide Approved Phase 4 851199-59-2 65351
Metronidazole Approved Phase 4 443-48-1 4173
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
Ofloxacin Approved Phase 4 82419-36-1 4583
Misoprostol Approved Phase 4 59122-46-2 5282381
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
Famotidine Approved Phase 4 76824-35-6 3325
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
Rebamipide Investigational Phase 4 90098-04-7
39 Phosphodiesterase Inhibitors Phase 4
40 Antioxidants Phase 4
41 Liver Extracts Phase 4
42 Antifibrinolytic Agents Phase 4
43 Phosphodiesterase 3 Inhibitors Phase 4
44 Laxatives Phase 4
45 Cathartics Phase 4
46 Serotonin Receptor Agonists Phase 4
47 Purinergic P2Y Receptor Antagonists Phase 4
48 glucocorticoids Phase 4
49 Antineoplastic Agents, Hormonal Phase 4
50 Antiemetics Phase 4

Interventional clinical trials:

(show top 50) (show all 349)
# Name Status NCT ID Phase Drugs
1 Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding. Unknown status NCT00414713 Phase 4
2 Optimal Anti-Platelet Treatment for Patients With Stent IMplantation And Clopidogrel Low Response: OPTIMAL Study Unknown status NCT01955200 Phase 4 Ticagrelor;Clopidogrel;Cilostazol;Clopidogrel;Clopidogrel
3 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
4 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
5 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
6 A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population Unknown status NCT02618382 Phase 4 Tranexamic Acid
7 The Comparison of Oral Rabeprazole vs. Intravenous Omeprazole in the Treatment of Patients With Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT00861640 Phase 4 Intravenous Omeprazole;Oral Rabeprazole
8 A Double Blind Study Comparing Low Dose and High Dose IV Esomeprazole After Successful Endoscopic Therapy in Patients With Peptic Ulcer Bleeding Unknown status NCT01275937 Phase 4 Esomeprazole;esomeprazole
9 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
10 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Unknown status NCT03023189 Phase 4 Tranexamic acid;Placebo
11 Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
12 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
13 A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Oral Ibuprofen in Management of Mild to Moderate Pain in Adult Patients in the ED Completed NCT03441269 Phase 4 Oral Ibuprofen
14 Possible Drug Interaction Between Clopidogrel and Ranitidin or Omeprazole in Patients With Stable Coronary Heart Disease: a Comparative Study Completed NCT01896557 Phase 4 omeprazole;Ranitidine;Clopidogrel
15 The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy Completed NCT00840008 Phase 4
16 Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) Completed NCT02467621 Phase 4 Pantoprazole
17 Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine Completed NCT00950339 Phase 4 omeprazole, 20mg twice daily;famotidine 40mg twice daily;pantoprazole 40mg once daily
18 Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage: A Double-Blind, Randomized, Placebo-Controlled Trial Completed NCT02903017 Phase 4 Tranexamic acid 5%;Placebo
19 A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy in Patients With Massive Overt Obscure Gastrointestinal Bleeding Completed NCT01654770 Phase 4
20 Single Blind, Randomized, Controlled Trial of Conventional Versus Split-Dose Bowel Preparation for Inpatient Colonoscopy Completed NCT01169220 Phase 4 Go-Lytely;Go Lytely
21 Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy Completed NCT02718261 Phase 4 Pantoprazole;Saline 0.9% (matching placebo)
22 Comparison of the Efficacy of Compliant Oral Iron Treatment (FerroDuretter ®) for 3 Months After Discharge Versus Single-dose of Intravenous Iron (Ferinject ®) Before Discharge in Patients With Acute Bleeding From Upper Gastrointestinal Tract. A Double Blinded Randomized Trial Completed NCT00978575 Phase 4 ferricarboxymaltose;Ferrosulfate;Placebo
23 Randomized Controlled Trial of Wireless Capsule Endoscopy in the Evaluation of Obscure Gastrointestinal Bleeding Completed NCT01006824 Phase 4
24 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection —a Prospective Randomized Controlled Study Completed NCT01914692 Phase 4 Somatostatin
25 Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding. Completed NCT01727453 Phase 4 warfarin;Bemiparina
26 A Prospective, Randomized, Double-blind, Double-dummy, Sucralfate Controlled, Multicenter Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis Completed NCT01284647 Phase 4 Teprenone capsule and placebo of sucralfate;Sucralfate and placebo of teprenone
27 A Multi-centre Proof of Concept Study to Assess Efficacy and Safety of a New Liquid Endoscopic Hemostatic Agent (Seraseal / Fastact ®) in Patients With Active Gastrointestinal Bleeding Completed NCT02349490 Phase 4
28 The Protection of Telipression on Developing of Acute Kidney Injury in Cirrhotic Patients With Upper-gastroentestinal Bleeding Completed NCT04358016 Phase 4 Terlipressin;Somatostatin
29 A Randomized, Controlled, Multicentric Trial Comparing Endoscopic Band Ligation Versus Ransjugular Intrahepatic Portosystemic Stent Shunt in Cirrhotic Patients With Recurrent Variceal Bleeding Non Responding to Medical Therapy Completed NCT00570973 Phase 4
30 Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response. Completed NCT00450164 Phase 4 Nadolol;Isosorbide mononitrate;Prazosin
31 Comparison Of Efficacy Of Two Immunosuppressive Protocols Including Tacrolimus With Or Without Mycophenolate Mofetil In Pediatric Liver Transplantation Aimed In Early Termination Of Steroid Therapy Completed NCT00195988 Phase 4 tacrolimus, steroids, mycophenolate mofetil
32 Effects of Different Omeprazole Dosing on Gastric pH in Non- Variceal Upper Gastrointestinal Bleeding: A Randomized Prospective Study Completed NCT03980496 Phase 4 Omeprazole
33 Appropriate Time Interval for Repeat Sessions of Endoscopic Ligation for the Eradication of Esophageal Varices Completed NCT01291277 Phase 4
34 Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed Completed NCT00369694 Phase 4 Terlipressin;Terlipressin & then Dummy
35 Administration of Intravenous Proton Pump Inhibitor Prior to Endoscopy [APPE] in Patients With Upper Gastrointestinal Bleeding; a Double-Blind Placebo-Controlled Randomised Study. Completed NCT00164866 Phase 4 Omeprazole
36 A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management in the Emergency Department" Completed NCT02078492 Phase 4 10 mg of Ketorolac;15 mg of Ketorolac;30 mg of Ketorolac
37 Does Acetaminophen Potentiate the Gastroduodenal Mucosal Injury of Aspirin? A Prospective, Randomized, Pilot Study. Completed NCT00594867 Phase 4 Acetaminophen - 4 grams per day + Placebo;Aspirin - 325 mg per day + Placebo;Acetaminophen 4 gram per day + Aspirin 325 mg per day
38 Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
39 Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy Completed NCT02049762 Phase 4 Aspirin
40 Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit Completed NCT00633035 Phase 4 esomeprazole 40 mg;famotidine 20 mg
41 Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study Completed NCT00844675 Phase 4 rabeprazole;placebo
42 Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
43 The Effect of Systemic Prophylactic Dexamethasone on the Incidence of Postoperative Sore Throat in Patients Undergoing Ambulatory Laparoscopic Gynecologic Surgery: A Prospective, Randomized, Double Blinded, Placebo Controlled Trial Completed NCT01052038 Phase 4 Placebo administration;Dexamethasone 0.05mg/kr administration;Dexamethasone 0.1mg/kg
44 Randomised Comparison of T-stenting Versus Culotte Technique for the Treatment of de Novo Coronary Bifurcation Lesion With Drug-eluting Stents. Completed NCT01267838 Phase 4
45 Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding Completed NCT00838864 Phase 4 ceftrioxone;ceftrioxone
46 Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis Completed NCT01310790 Phase 4
47 Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding Completed NCT01806090 Phase 4 clopidogrel
48 Sequential Helicobacter Pylori Eradication Therapy in Myanmar; a Randomized Clinical Trial of Efficacy and Tolerability Completed NCT04132479 Phase 4 Clarithromycin 500mg;Amoxicillin 500mg;Tinidazole 500mg;Rabeprazole 20mg;Clarithromycin 500mg;Amoxicillin 500mg;Tinidazole 500mg;Rabeprazole 20mg
49 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
50 Intravenous Administration of Metronidazole, Levofloxacin and Esomeprazole Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease Recruiting NCT04432233 Phase 4 Esomeprazole;Metronidazole;Levofloxacin

Search NIH Clinical Center for Active Peptic Ulcer Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
basic aluminum carbonate gel
Calcium Carbonate
Calcium gluceptate
dihydroxyaluminum sodium carbonate
Magnesium Hydroxide
Vasopressin (USP)

Genetic Tests for Active Peptic Ulcer Disease

Anatomical Context for Active Peptic Ulcer Disease

MalaCards organs/tissues related to Active Peptic Ulcer Disease:

Liver, Colon, Testes, Heart, Lung, Kidney, Small Intestine

Publications for Active Peptic Ulcer Disease

Articles related to Active Peptic Ulcer Disease:

(show top 50) (show all 2918)
# Title Authors PMID Year
Comparative safety of flavocoxid vs prescription NSAIDs among osteoarthritis patients. 61
32305527 2020
Prophylactic use of acid suppressants in adult acutely ill hospitalised patients: A systematic review with meta-analysis and trial sequential analysis. 61
32060905 2020
High rate of re-bleeding after application of Hemospray for upper and lower gastrointestinal bleeds. 61
32127325 2020
Thalidomide Use Reduces Risk of Refractory Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices. 61
31425265 2020
Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen. 61
32500272 2020
Efficacy of the OTSC System in the treatment of GI bleeding and wall defects: a PMCF meta-analysis. 61
30957599 2020
Risk of Pump Thrombosis and Stroke in Patients with Continuous-Flow Left Ventricular Assist Devices and Gastrointestinal Bleeding. 61
32530086 2020
Use of rapid reading software to reduce capsule endoscopy reading times while maintaining accuracy. 61
31981645 2020
Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis. 61
31791903 2020
AGA Clinical Practice Update on Endoscopic Therapies for Non-Variceal Upper Gastrointestinal Bleeding: Expert Review. 61
32574620 2020
Fluoroscopy-guided endoscopic sclerotherapy: a novel hybrid approach for symptomatic rectosigmoidal venous malformation (with video). 61
32553568 2020
The gut microbes, Enterococcus and Escherichia-Shigella, affect the responses of heart valve replacement patients to the anticoagulant warfarin. 61
32505835 2020
What gastroenterologists should know about direct oral anticoagulants. 61
32532603 2020
A combination of single-balloon enteroscopy-assisted laparoscopy and endoscopic mucosal resection for treating gastrointestinal venous malformations in blue rubber bleb nevus syndrome: a case report. 61
32522148 2020
Can the Computed Tomographic Aspect of Porto-Systemic Circulation in Cirrhotic Patients be Associated with the Presence of Variceal Hemorrhage? 61
32575407 2020
The severity of anemia does not correlate with the risk of gastrointestinal cancer in subsequent evaluation. 61
32568557 2020
Non-steroidal anti-inflammatory drug-induced enteropathy as a major risk factor for small bowel bleeding: a retrospective study. 61
32513198 2020
The Dilemma in the Management of GI Bleeding During the COVID-19 Pandemic. 61
32544397 2020
When ESKD complicates disease management: GI bleeding and other GI illnesses. 61
32274868 2020
Treatment of gastrointestinal bleeding in left ventricular assist devices: A comprehensive review. 61
32523310 2020
An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. 61
32432841 2020
Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies. 61
32397355 2020
Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience. 61
32202691 2020
Post-Blunt Traumatic Hemobilia From Pseudoaneurysm Successfully Treated With Embolization. 61
32382469 2020
Determinants of empiric transfusion in gastrointestinal bleeding in the emergency department. 61
31864876 2020
Hemostatic spray powder TC-325 in the primary endoscopic treatment of peptic ulcer related bleeding: multicentre international registry. 61
32459000 2020
An Unusual Cause of Lower Gastrointestinal Bleeding: Cecal Dieulafoy's Lesion. 61
32499973 2020
What is the impact of the adjunctive use of omega-3 fatty acids in the treatment of periodontitis? A systematic review and meta-analysis. 61
32438906 2020
Decline in acute upper gastrointestinal bleeding during Covid-19 pandemic after lockdown in Austria. 61
32408356 2020
Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care. 61
32476788 2020
Risks and Outcomes of Gastrointestinal Malignancies in Anticoagulated Atrial Fibrillation Patients Experiencing Gastrointestinal Bleeding - A Nationwide Cohort Study. 61
32470625 2020
Natural history of upper and lower gastrointestinal bleeding in hemodialysis patients: A dual-center long-term cohort study. 61
32432811 2020
Coexistence of Von Willebrand disease and gastrointestinal stromal tumor (G.I.S.T): Case report of a rare and challenge association. 61
32444278 2020
Readmissions Rates After Myocardial Infarction for Gastrointestinal Bleeding: A National Perspective. 61
32436123 2020
Embolization of congenital portosystemic shunt presenting after pediatric liver transplantation: Case report and literature review. 61
32406984 2020
Acute hemorrhagic rectal ulcer: Experience in 11 patients at an urban acute care center in the USA: A case series. 61
32358354 2020
Fatal secondary aortoduodenal fistula diagnosed with postmortem computed tomography angiography. 61
32394207 2020
Gastrointestinal involvement of primary skin diseases. 61
32455473 2020
Real World Experience with the HeartMate 3 (HM3) Left Ventricular Assist Device (LVAD): Analysis of the First 125 Consecutive Patients at a Single Institution. 61
32465450 2020
Significant Restrictive or Obstructive Lung Diseases are Associated with an Increased Risk of Gastrointestinal Bleeding in Patients on Left Ventricular Assist Device Support. 61
32465615 2020
Meld Scoring System to Predict Outcomes in Patients Who Undergo VV ECMO Implantation. 61
32465593 2020
Heartmate 3 Implantation in Cancer Survivors with Advanced Heart Failure. 61
32465010 2020
Increased Right Heart Failure (RHF) in High BMI LVAD Recipients. 61
32465572 2020
Impact of Heart Failure Drug Therapy on GI Bleeding Rates in LVAD Recipients: An INTERMACS Analysis. 61
32465225 2020
Heart Failure Duration Association with Gastrointestinal Bleeding Post Left Ventricular Assist Device. 61
32465614 2020
Use of Thalidomide for Refractory GI Bleeding in Patients with Continuous Flow Left Ventricular Assist Device (cfLVAD) - The Western Australian (WA) Experience. 61
32465625 2020
Endo-gastric Teratoma - A Rare Cause of Upper GI Bleeding in an Infant! 61
31713214 2020
Concerns regarding the recommendations of the British Society of Gastroenterology's lower GI bleeding guidelines. 61
30996044 2020
Outcomes in lower GI bleeding comparing weekend with weekday admission. 61
32330505 2020
Outcomes of Patients Bridged with Acute Mechanical Circulatory Support Devices to HeartMate 3. 61
32465021 2020

Variations for Active Peptic Ulcer Disease

Expression for Active Peptic Ulcer Disease

Search GEO for disease gene expression data for Active Peptic Ulcer Disease.

Pathways for Active Peptic Ulcer Disease

Pathways related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
Show member pathways
11.96 VWF F7 F3 F2
2 11.9 VWF F7 F3 F2
Show member pathways
4 11.76 VWF PTGS1 P2RY12 F2
Show member pathways
11.69 PTGS2 PTGS1 CYP3A4 CYP2C19
6 11.64 VWF PTGS2 F3
Show member pathways
11.55 P2RY12 CYP3A4 CYP2C19
Show member pathways
11.11 KIT CYP3A4 CYP2C19
9 10.81 VWF PTGS1 P2RY12 F2 CYP3A4 CYP2C19
10 10.71 PTGS2 PTGS1 CRP
11 10.51 PTGS2 PTGS1 CYP3A4
12 10.18 HRH2 ATP4A

GO Terms for Active Peptic Ulcer Disease

Cellular components related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 SST KIT F7 F3 F2 CRP
2 organelle membrane GO:0031090 9.26 PTGS2 PTGS1 CYP3A4 CYP2C19
3 serine-type peptidase complex GO:1905286 8.62 F7 F3

Biological processes related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 xenobiotic metabolic process GO:0006805 9.71 PTGS1 CYP3A4 CYP2C19
2 cellular oxidant detoxification GO:0098869 9.67 PTGS2 PTGS1 ALB
3 fatty acid metabolic process GO:0006631 9.67 PTGS2 PTGS1 CYP3A4 CYP2C19
4 regulation of blood pressure GO:0008217 9.63 PTGS2 PTGS1 ACVRL1
5 positive regulation of protein kinase B signaling GO:0051897 9.62 P2RY12 KIT F7 F3
6 sodium ion export across plasma membrane GO:0036376 9.58 ATP4A ATP12A
7 positive regulation of blood coagulation GO:0030194 9.57 F7 F2
8 cellular potassium ion homeostasis GO:0030007 9.56 ATP4A ATP12A
9 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.55 ATP4A ATP12A
10 positive regulation of positive chemotaxis GO:0050927 9.52 F7 F3
11 cyclooxygenase pathway GO:0019371 9.51 PTGS2 PTGS1
12 negative regulation of blood vessel diameter GO:0097756 9.48 PTGS2 CRP
13 heterocycle metabolic process GO:0046483 9.43 CYP3A4 CYP2C19
14 monoterpenoid metabolic process GO:0016098 9.4 CYP3A4 CYP2C19
15 blood coagulation GO:0007596 9.35 VWF P2RY12 F7 F3 F2
16 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.26 F7 F3
17 blood coagulation, extrinsic pathway GO:0007598 9.16 F7 F3
18 hemostasis GO:0007599 9.02 VWF P2RY12 F7 F3 F2

Molecular functions related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.73 PTGS2 PTGS1 KIT FLG2 CYP3A4 CYP2C19
2 heme binding GO:0020037 9.62 PTGS2 PTGS1 CYP3A4 CYP2C19
3 sodium:potassium-exchanging ATPase activity GO:0005391 9.4 ATP4A ATP12A
4 potassium-transporting ATPase activity GO:0008556 9.37 ATP4A ATP12A
5 oxygen binding GO:0019825 9.33 CYP3A4 CYP2C19 ALB
6 potassium:proton exchanging ATPase activity GO:0008900 9.26 ATP4A ATP12A
7 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS2 PTGS1

Sources for Active Peptic Ulcer Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....